ARROW study: pralsetinib in RET fusion+ tumors

ARROW study: pralsetinib in RET fusion+ tumors

ARROW points the way for RET fusion-positive NSCLC treatment | Stephen LiuПодробнее

ARROW points the way for RET fusion-positive NSCLC treatment | Stephen Liu

ARROW update confirms pralsetinib benefit for RET fusion-positive advanced NSCLC | Stephen LiuПодробнее

ARROW update confirms pralsetinib benefit for RET fusion-positive advanced NSCLC | Stephen Liu

Pralsetinib in Chinese patients with advanced RET fusion+ NSCLCПодробнее

Pralsetinib in Chinese patients with advanced RET fusion+ NSCLC

ASCO 2021 - Blueprint Medicines - ARROW Study Updated ResultsПодробнее

ASCO 2021 - Blueprint Medicines - ARROW Study Updated Results

ARROW: clinical activity of pralsetinib in RET-fusion positive solid tumorsПодробнее

ARROW: clinical activity of pralsetinib in RET-fusion positive solid tumors

ARROW: an update on the registrational studyПодробнее

ARROW: an update on the registrational study

ARROW: precision targeted therapy with pralsetinib for RET fusion+ tumorsПодробнее

ARROW: precision targeted therapy with pralsetinib for RET fusion+ tumors